Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOX1 | Q06278 | 1/20 | 0.43 |
| ▸ | CFTR | P13569 | 1/20 | 0.36 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.34 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6523567 | 0.82 | TSHR (0.41) | CFTRGABRA1GABRB2TSHRALDH1A1 | |
| SCHEMBL6522210 | 0.78 | GABRA1 (0.41) | CFTRGABRA1GABRB2TSHRALDH1A1 | |
| SCHEMBL5002506 | 0.75 | GABRA1 (0.39) | CFTRGABRA1GABRB2TSHRALDH1A1 | |
| SCHEMBL344617 | 0.74 | PTK2B (0.46) | GABRA1GABRB2TSHRALDH1A1PTPN5 | |
| SCHEMBL20526222 | 0.74 | GABRA1 (0.44) | CFTRGABRA1GABRB2TSHRALDH1A1 | |
| Hydrochloric Acid SCHEMBL10824664 | 0.72 | PTK2B (0.44) | GABRA1GABRB2TSHRALDH1A1PTPN5 | |
| SCHEMBL777944 | 0.71 | PTPN5 (0.40) | CFTRGABRA1GABRB2ALDH1A1PTPN5 | |
| SCHEMBL10448564 | 0.71 | GABRA1 (0.41) | GABRA1GABRB2TSHRALDH1A1CYP1A2 | |
| SCHEMBL2536276 | 0.71 | GABRA1 (0.41) | CFTRGABRA1GABRB2TSHRALDH1A1 | |
| SCHEMBL29019759 | 0.70 | TSHR (0.47) | TSHRCYP3A4CYP2C9HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9026372-B2 | Methods for providing a system of care for a high-dose oxazaphosphorine drug regimen | ACCENTIA BIOPHARMACEUTICALS, INC. (US) | 2015-05-05 | — | — | US | disclosed |
| US-20110117050-A1 | Methods for Providing a System of Care for an Oxazaphosphorine Drug Regimen | ACCENTIA BIOPHARMACEUTICALS, INC. (US) | 2011-05-19 | — | — | US | disclosed |
| US-20110097426-A1 | Methods for Safe and Effective Treatment Using Oxazaphosphorine Drugs | ACCENTIA BIOPHARMACEUTICALS, INC. (US) | 2011-04-28 | — | — | US | disclosed |
| US-20110082115-A1 | Methods for Providing a System of Care for an Oxazaphosphorine Drug Regimen | ACCENTIA BIOPHARMACEUTICALS, INC. (US) | 2011-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110117050-A1 | Methods for Providing a System of Care for an Oxazaphosphorine Drug Regimen | PAICS, TYMP, OTC | AOX1 488/4885CFTR 4657/4885GABRA1 4058/4885 |
| US-20110082115-A1 | Methods for Providing a System of Care for an Oxazaphosphorine Drug Regimen | PAICS, TYMP, OTC | AOX1 488/4885CFTR 4657/4885GABRA1 4058/4885 |
| US-20110097426-A1 | Methods for Safe and Effective Treatment Using Oxazaphosphorine Drugs | TYMP, PAICS, ENTPD5 | AOX1 630/4885CFTR 4823/4885GABRA1 3118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.